隐形眼镜业务板块高速扩张，产能持续爬坡。2024 年公司隐形眼镜收入达4.3亿元，占营收比重提升至 30.2%（+15.9pp）。公司通过收并购天眼医药、福建优你康快速切入并拓展隐形眼镜市场，目前处于产 能扩张和效率提升期。随着产能释放、良率提升以及高附加值的硅水凝胶产品的推出，该板块有望持续 贡献业绩增量并改善盈利能力。 盈利预测：预计2025-2027 年EPS 分别为2.64 元、3.46 元、4.31 元。 风险提示：政策风险；产品研发不及预期风险；医疗事故风险；市场竞争加剧风险。 24 年业绩符合预期，隐形眼镜业务表现亮眼。公司2024 年收入增速48.2%，归母净利润增速27.8%，业 绩符合预期。分业务看，人工晶体业务实现收入5.9亿元（+17.7%），销量同比增长44.9%，收入增速略 低于销量主要受集采降价影响。角膜塑形镜（OK 镜）实现收入2.4亿元（+8.0%），增速有所放缓主要 因行业竞争加剧及消费环境改变。隐形眼镜业务表现亮眼，实现收入4.3 亿元（+211.8%），销量同比 增长241.1%，成为公司增长主要驱动力。 研发投入持续加大，在研管线储备丰富。2024 年公司研发费用达1 ...

爱博诺德(北京)医疗科技股份有限公司的主营业务是眼科医疗器械的自主研发、生产、销售及相关服 务。公司的主要产品是人工晶状体、其他手术产品、角膜塑形镜、其他近视防控产品、隐形眼镜、其他 视力保健产品。 最新一期业绩显示，2025年一季报，公司实现营业收入3.57亿元，同比15.07%；净利润9255.81万元， 同比-10.05%，销售毛利率64.60%。 4月28日，爱博医疗今日收盘79.25元，下跌2.92%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到39.73倍，总市值150.21亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.40倍，行业中值34.81倍，爱博医疗排 名第82位。 截至2025年一季报，共有67家机构持仓爱博医疗，其中基金62家、其他5家，合计持股数6774.00万股， 持股市值66.37亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)82爱博医疗39.7338.676.14150.21亿行业平均 46.4044.004.49100.23亿行业中值34.8134.782.2645.22亿1硕世生物-1850.69-1850.691.14 ...

2025 年 04 月 27 日 公司研究 评级：买入(维持) 研究所： 证券分析师： 李明 S0350523090001 lim06@ghzq.com.cn [Table_Title] 一季度利润下滑，看好龙晶等业务的长期成长性 ——爱博医疗（688050）2024 年年报和 2025 年 一季报点评 最近一年走势 | 相对沪深 | 300 | 表现 | | 2025/04/25 | | --- | --- | --- | --- | --- | | 表现 | | 1M | 3M | 12M | | 爱博医疗 | | -12.4% | -17.9% | 6.9% | | 沪深 300 | | -3.7% | -1.2% | 7.3% | | 市场数据 | 2025/04/25 | | --- | --- | | 当前价格（元） | 81.63 | | 周价格区间（元） 52 | 65.17-159.80 | | 总市值（百万） | 15,472.52 | | 流通市值（百万） | 15,472.52 | | 总股本（万股） | 18,954.45 | | 流通股本（万股） | 18,954.45 | | 日 ...

1. 人工晶体业务整体稳健，隐形眼镜加速爬坡，集采及产品结构改变致使盈利水平暂时承压。分业务板 块看，2024 年公司"普诺明""全视"等人工晶状体销量同比增长44.93%，贡献营收5.88 亿元 （+17.66%）；"普诺瞳"角膜塑形镜销量同比增长2.4%，贡献营收2.36 亿元（+8.03%），离焦镜等加速 放量，带动近视防控板块营收实现20.8%的增长；隐形眼镜随着产能持续爬坡，实现销量同比增长 241.11%，贡献营收4.26 亿元（+211.84%）。随着人工晶体集采全面落地执行、价格水平下调，而高端 晶体占比仍较低，以及低毛利隐形眼镜业务占比进一步提升至30.21%（+15.85pct），公司整体毛利率 下滑至66.23%（-9.78pct）；25Q1，人工晶体业务持续受集采影响，价格下调，终端手术量减少，同时 角膜塑形镜市场竞争加剧、出厂价格略有下调，加之隐形眼镜业务利润贡献有限，公司整体毛利率进一 步下滑至64.6%。公司在产品端持续推进晶体、近视防控的高端产品上市，加速隐形眼镜业务的生产规 模扩大和生产端优化，同时在渠道端推进全球网络建设，国内协同院内院外、零售等多渠道销售，海外 覆盖德国、 ...

Core Viewpoint - Aibo Medical continues to drive high-quality development through ESG principles, showcasing a balance between technological leadership and social responsibility, with a focus on core products and a dual strategy of "medical + consumer" [2] Environmental Dimension - Aibo Medical has been recognized as a water-saving enterprise in Beijing and has implemented water-saving technologies such as membrane separation and rainwater harvesting for irrigation [3] - The company has achieved ISO 50001 energy management certification and improved energy efficiency through various initiatives, including variable frequency technology and energy-saving lighting, expected to save nearly 10,000 kWh annually [3] Social Dimension - Aibo Medical has established the "Puno Tong Starfire Program" in collaboration with five universities to cultivate talent and has organized 61 academic conferences, enhancing industry standards and academic influence [3] - The company has partnered with Meituan to launch the first 24-hour smart store for contact lenses, improving consumer convenience through automation [3] Governance Dimension - Aibo Medical's R&D investment reached 160 million yuan in 2024, a year-on-year increase of 20.8%, with a total of 417 patent applications and 256 granted patents [5] - The company has been recognized for its governance transparency, receiving an A-level rating for information disclosure from the Shanghai Stock Exchange for two consecutive years [2] ESG Challenges - Aibo Medical was removed from the "Huaxia-Wind ESG Dandelion 50 Index" due to a decline in ESG scores, indicating areas for improvement in climate action and resource recycling disclosures [6] - The company lacks quantifiable targets for carbon emissions reduction and renewable energy usage, which are critical for assessing its climate action effectiveness [7] - There is insufficient disclosure regarding waste management and resource recycling, making it difficult to evaluate the company's environmental performance [7][8] Employee Welfare - While Aibo Medical has implemented measures for employee rights and training, there is a need for improvement in the depth and breadth of employee care compared to industry leaders [8] - The company has not disclosed detailed employee demographics or turnover rates, limiting external understanding of its human resource management practices [8] Quality Control - Aibo Medical faced a product recall due to a quality issue with a specific batch of soft hydrophilic contact lenses, highlighting the importance of quality management alongside capacity expansion [9]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has shown strong revenue growth in 2024, achieving 1.41 billion yuan, a year-on-year increase of 48.24%, while net profit attributable to the parent company reached 388 million yuan, up 27.77% [1][2] - The growth in the contact lens segment is robust, with a significant increase in revenue, and the company is optimistic about the launch of high-end new products in 2025 [2][3] - The profit growth rate is lagging behind revenue growth due to fluctuations in gross margins, influenced by intensified competition in the artificial lens and orthokeratology markets [2][3] Revenue and Profit Analysis - In 2024, the company reported revenue of 1.41 billion yuan, with a gross margin of 66.23%, down 9.78 percentage points year-on-year [2] - For Q1 2025, revenue was 357 million yuan, a 15.07% increase year-on-year, but net profit decreased by 10.05% [1][2] - The company’s gross margins for 2024 and Q1 2025 were 66.23% and 64.60%, respectively, reflecting the impact of competitive pricing and a higher proportion of lower-margin products [2] Segment Performance - Contact lenses generated revenue of 426 million yuan in 2024, a remarkable increase of 211.84%, with a gross margin of 26.18% [3] - Revenue from artificial lenses was 588 million yuan, up 17.66%, with a gross margin of 89.16% [3] - The orthokeratology lens segment saw revenue of 236 million yuan, an 8.03% increase, with a gross margin of 85.68% [3] Market Expansion - Domestic revenue reached 1.36 billion yuan in 2024, a 49.52% increase, while overseas revenue was 46 million yuan, up 16.73% [4] - The company has established a comprehensive domestic sales network covering over 6000 hospitals and optical centers across 31 provinces and municipalities [4] - Internationally, the company has expanded its sales network to Europe, Asia, and Oceania, with products recognized in over 30 countries [4] Financial Forecast - Revenue projections for 2025-2027 are 1.82 billion yuan, 2.38 billion yuan, and 3.07 billion yuan, with year-on-year growth rates of 29.2%, 30.5%, and 29.1% respectively [4] - Net profit forecasts for the same period are 469 million yuan, 585 million yuan, and 725 million yuan, with growth rates of 20.8%, 24.8%, and 23.9% respectively [4]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has shown strong revenue growth in 2024, achieving 1.41 billion yuan, a year-on-year increase of 48.24%, while net profit attributable to shareholders reached 388 million yuan, up 27.77% [1] - The growth in the contact lens segment is robust, with a significant increase in revenue, and the company is optimistic about the launch of high-end new products in 2025 [2][3] - The profit growth rate is lagging behind revenue growth due to fluctuations in gross margins, influenced by increased competition and pricing pressures in the artificial lens and orthokeratology markets [2] Revenue and Profit Analysis - In 2024, the company reported revenue of 1.41 billion yuan, with a gross margin of 66.23%, down 9.78 percentage points year-on-year [2] - For Q1 2025, revenue was 357 million yuan, reflecting a 15.07% year-on-year growth, but net profit decreased by 10.05% [1] - The contact lens segment generated 426 million yuan in revenue, a remarkable increase of 211.84%, while the artificial lens segment saw revenue of 588 million yuan, up 17.66% [3] Market Expansion - Domestic sales reached 1.36 billion yuan, a 49.52% increase, while overseas sales were 46 million yuan, up 16.73% [4] - The company has established a comprehensive domestic sales network covering over 6000 hospitals and optical centers across 31 provinces and regions [4] - Internationally, the company has expanded its sales network to Europe, Asia, and Oceania, with products exported to over 30 countries [4] Financial Forecast - Revenue projections for 2025-2027 are 1.82 billion yuan, 2.38 billion yuan, and 3.07 billion yuan, respectively, with year-on-year growth rates of 29.2%, 30.5%, and 29.1% [4] - Net profit forecasts for the same period are 469 million yuan, 585 million yuan, and 725 million yuan, with growth rates of 20.8%, 24.8%, and 23.9% [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a robust revenue growth of 48.24% year-on-year for 2024, achieving total revenue of 1.41 billion yuan and a net profit of 388 million yuan, which is a 27.77% increase year-on-year [3] - The first quarter of 2025 showed a revenue of 357 million yuan, reflecting a year-on-year growth of 15.07%, although net profit decreased by 10.05% to 93 million yuan [3] - The company is positioned as a platform-type enterprise with strong R&D capabilities and commercial potential, with a focus on artificial crystalline lenses and myopia control products [8] Summary by Sections Business Performance - The artificial crystalline lens segment saw sales volume of approximately 1.7385 million pieces in 2024, a year-on-year increase of 44.93%, generating sales revenue of about 588 million yuan, up 17.66% year-on-year [4] - The myopia control business generated approximately 336 million yuan in revenue, a growth of 20.79% year-on-year, with OK lens sales contributing 236 million yuan, an 8.03% increase [5] - The vision care segment reported revenue of approximately 426 million yuan, a significant increase of 211.84% year-on-year, with sales volume reaching 214 million pieces [6] Financial Projections - Revenue projections for 2025, 2026, and 2027 are estimated at 1.763 billion yuan, 2.247 billion yuan, and 2.810 billion yuan respectively, with growth rates of 25.1%, 27.4%, and 25.1% [9] - Net profit forecasts for the same years are 468 million yuan, 610 million yuan, and 776 million yuan, with growth rates of 20.5%, 30.3%, and 27.3% [9] - The expected EPS for 2025, 2026, and 2027 are 2.47 yuan, 3.22 yuan, and 4.10 yuan, with corresponding P/E ratios of 35x, 27x, and 21x [9] R&D and Market Position - The company invested approximately 159.82 million yuan in R&D in 2024, representing 11.33% of its revenue, indicating a strong commitment to innovation [8] - The company has established a sales network covering over 6,000 hospitals and vision centers across 31 provinces, enhancing its market reach [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a robust revenue growth of 48.24% year-on-year for 2024, achieving total revenue of 1.41 billion yuan and a net profit of 388 million yuan, which is a 27.77% increase year-on-year [3] - The first quarter of 2025 showed a revenue of 357 million yuan, reflecting a year-on-year growth of 15.07%, although net profit decreased by 10.05% [3] - The company is positioned as a platform-type enterprise with strong R&D capabilities and commercial potential, with a focus on expanding its product offerings in the ophthalmic sector [8] Summary by Sections Business Performance - The artificial lens business saw sales volume reach approximately 1.7385 million pieces in 2024, a year-on-year increase of 44.93%, generating sales revenue of about 588 million yuan, up 17.66% year-on-year [4] - The myopia prevention business generated approximately 336 million yuan in revenue, a growth of 20.79% year-on-year, with OK lens sales contributing 236 million yuan [5] - The vision care business reported revenue of approximately 426 million yuan, a significant increase of 211.84% year-on-year, with sales volume reaching 214 million pieces [6] Financial Projections - Revenue projections for 2025, 2026, and 2027 are estimated at 1.763 billion yuan, 2.247 billion yuan, and 2.810 billion yuan, respectively, with growth rates of 25.1%, 27.4%, and 25.1% [9] - The net profit for the same years is projected to be 468 million yuan, 610 million yuan, and 776 million yuan, with growth rates of 20.5%, 30.3%, and 27.3% [9] - The expected EPS for 2025, 2026, and 2027 are 2.47 yuan, 3.22 yuan, and 4.10 yuan, with corresponding P/E ratios of 35x, 27x, and 21x [9] R&D and Market Position - The company invested approximately 159.82 million yuan in R&D in 2024, representing 11.33% of its revenue, indicating a strong commitment to innovation [8] - The company has established a sales network covering over 6,000 hospitals and vision centers across China, enhancing its ability to commercialize new products [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.41 billion yuan in 2024, representing a year-on-year growth of 48.24%, and a net profit attributable to shareholders of 388 million yuan, up 27.77% year-on-year [8] - The first quarter of 2025 is expected to face short-term pressure due to the impact of national centralized procurement policies on artificial crystalline lenses, leading to a decrease in surgical volumes and prices [8] - The company anticipates a recovery in its artificial lens business as new products, such as bifocal lenses and PR crystals, gradually gain market traction [8] Financial Summary - Total revenue forecast for 2024 is 1.41 billion yuan, with a projected growth rate of 48.24% [9] - Net profit attributable to shareholders is expected to be 388 million yuan in 2024, with a growth rate of 27.77% [9] - Earnings per share (EPS) is projected to be 2.05 yuan in 2024, with a price-to-earnings (P/E) ratio of 41.96 [9] - The company’s total assets are estimated to reach 4.08 billion yuan by 2025, with a debt-to-asset ratio of 24.01% [9]